Recently, epidermal growth factor receptor (EGFR) was a key molecule in investigation of lung cancer, and it was a target for a new therapeutic strategy, based on molecular analyses. In this review, we have summarized some issues considering the role of EGFR in lung cancer, its coding gene, and its promoter gene polymorphisms (SNPs) -216G/T and -191C/A in non-small-cell lung cancer (NSCLC). The position of the SNPs indicates their significant role in EGFR regulation. The accumulation of knowledge regarding SNPs lately suggests their significant and important role in the onset of carcinogenesis, the prediction of the onset of metastases, the response to therapy with TKI inhibitors, and the onset of toxic effects of the applied therapy. Based on this, we suggest further studies of the relationship of clinical significance to SNPs in patients with lung tumors.

中文翻译：

---

非小细胞肺癌中的表皮生长因子受体基因：启动子多态性研究的重要性。

最近，表皮生长因子受体（EGFR）是肺癌研究中的关键分子，基于分子分析，它是新治疗策略的目标。在这篇综述中，我们总结了考虑EGFR在肺癌，其编码基因及其启动子基因多态性（SNP）-216G / T和-191C / A在非小细胞肺癌（NSCLC）中的作用的一些问题。 。SNP的位置表明它们在EGFR调节中的重要作用。最近有关SNP的知识的积累表明，它们在致癌作用的开始，转移的发作的预测，对TKI抑制剂的治疗反应以及所用治疗的毒性作用的开始中具有重要作用。基于此，